Initiate tiered Overweight on ISRG at $390 with hard stop $338 and Q3 binary catalyst
The Overweight rating with tiered architecture, $338 hard stop, and Q3 binary catalyst survives all binding constraints: 9/1 reflection forbids Underweight/Sell at 38% off highs with intact quality; 9/4 endorses tiered framework at defined zones; 9/14 addresses mid-tier drift via hard-dated catalyst and structural invalidation; the Conservative Analyst's timing risk is addressed via smaller starter (0.25-0.375% vs. typical 1.0-1.5% Overweight) with explicit scale-in zones; the Aggressive Analyst's fundamental asymmetry case is preserved via Overweight direction with quality-compounder thesis intact; Pure Hold is disqualified by 9/1 lesson forbidding passive non-action on accelerating fundamentals at deep drawdown.
| Position | Action |
|---|---|
| Current price within Tier 1 zone ($385-395) | Initiate starter tranche at 0.25-0.375% portfolio weight (~25% of intended 1.0-1.5% target) |
| Pullback to $370-380 zone with RSI 50-60, volume >2.5M shares, lower Bollinger band/50 SMA | Add ~35% of intended position; trailing stop $348 or $338 |
| Successful retest and hold of July capitulation low zone ($345-355) with bullish RSI divergence | Add final ~40% of intended position; trailing stop $322 |
ISRG is a category-defining business with accelerating fundamentals (18.5% revenue growth, 26.5% EPS growth, expanding margins) trading at its cheapest valuation in a decade, offering patient capital a multi-year compounding opportunity in a $200B+ TAM.
| Indicator | Value | Signal |
|---|---|---|
| Close | $382.29 | neutral |
| 10 EMA | 371.80 | bullish |
| 50 SMA | 374.48 | neutral |
| 200 SMA | 456.93 | bearish |
| RSI (14) | 55.40 | bullish |
| MACD line | -1.86 | neutral |
| MACD signal | -3.59 | bullish |
| MACD histogram | +1.74 | bullish |
| Bollinger Upper Band | 391.79 | neutral |
| Bollinger Middle Band | 371.57 | bullish |
| Bollinger Lower Band | 351.35 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $370-380 with RSI 50-60, volume >2.5M shares
Then: Add ~35% of intended position on pullback into lower Bollinger band/50 SMA zone
ISRG's current valuation is historically cheap despite superior business quality, with forward earnings actually supported by recent performance
ISRG is not a bargain but rather a high-quality compounder entering a multi-quarter deceleration phase in a hawkish macro regime with rising competitive intensity, with the recent bounce being a bear-market rally that will likely fail before the true bottom.
· concedes: The bull is correct that ISRG has a strong business with real moat via installed base, switching costs, and clinical superiority data; The 14M-procedure meta-analysis does demonstrate clinical superiority; da Vinci SP EU CE mark for transvaginal gynecology is incremental positive TAM expansion; The installed base consumables revenue does not go away in a 25bp rate move
→ vs conservative: Waiting for 'confirmed reversal above the 50 SMA on a weekly basis' means buying at $400+ and missing 20-40% of the recovery — that's performance anxiety masquerading as discipline, not risk management
→ vs conservative: The 200 SMA mean-reversion risk argument ignores that ISRG's earnings accelerated (not deteriorated) into the drawdown — a stock falling 38% on improving fundamentals is a gift, not a broken thesis
→ vs conservative: 'The 50 SMA is declining' and 'bounce volume is light' are setup conditions, not fundamental concerns — the conservative analyst cannot articulate an actual bear case for a debt-free compounder at a 10-year valuation low with expanding TAM
→ vs conservative: ISRG's end markets (surgical procedures on aging patients) are rate-insensitive; hospital systems don't cancel scheduled procedures because the Fed hiked 25 basis points — the macro bear case is a 'hiding place' that doesn't apply to this business model
→ vs neutral: 'Macro overrides fundamentals near-term' is precisely the thinking that causes investors to miss generational buying opportunities — the market has ALREADY priced the macro, which is why the stock is down 38% despite accelerating fundamentals
→ vs neutral: The question isn't whether macro is tough (it is) but whether macro is MORE reflected in the price today than it will be six months from now — at 31.6x forward earnings with 1.76 PEG, the answer is obviously yes
| neutral |
| ATR (14) | 11.75 | neutral |
Support: 371.57 · 351.35 · 332.02 | Resistance: 391.79 · 400 · 456.93
ISRG is trading at $382.29, recovering from a sharp July sell-off ( capitulation on 7/17 at $345.42 on 11.56M shares volume) but remains 16.3% below the 200 SMA at $456.93. Short-term indicators are constructive: price above 10 EMA (371.80) and 50 SMA (374.48), RSI recovering to 55.40 from oversold sub-30 levels, and MACD histogram positive (+1.74) after a bullish crossover on 8/25/2026. However, the 50 SMA is still declining, the 200 SMA is rolling over, and a death cross formed in early 2026 when the 50 SMA crossed below the 200 SMA. The setup reads as a bear-market relief rally: immediate resistance at $391.79 (Bollinger upper band), with key support at $351.35 (Bollinger lower band) and $332.02 (July panic low). With ATR elevated at $11.75 (≈3.1% of price), risk management is critical.
Market Cap
$136.97B
P/E (TTM)
43.89x
Forward P/E
31.62x
PEG Ratio
1.76
Price/Book
7.45x
EPS (TTM)
$8.71
Forward EPS
$12.09
Revenue Q2'26
$2,892M
Gross Profit Q2'26
$1,960M
Operating Income Q2'26
$972M
Net Income Q2'26
$818M
Diluted EPS Q2'26
$2.29
Gross Margin Q2'26
67.8%
Operating Margin Q2'26
33.6%
Net Profit Margin (TTM)
28.4%
Cash & ST Investments
$5,216M
Total Assets
$20,877M
Stockholders' Equity
$18,168M
Total Debt
~$0
Current Ratio
4.96x
Working Capital
$7.6B
TTM Free Cash Flow
$2.615B
Free Cash Flow Q2'26
$948M
Operating Cash Flow Q2'26
$1,061M
Return on Equity
17.4%
Return on Assets
10.5%
52-Week High
$603.88
52-Week Low
$328.57
50-Day Moving Avg
$375.39
200-Day Moving Avg
$457.89
Beta
1.465
Buybacks (Past 4 Quarters)
$3.7B
Strengths
Concerns
ISRG operates a capital-equipment-plus-recurring-revenue model as the global leader in robotic surgery with the da Vinci platform. Q2'26 results show strong execution with 18.5% revenue growth and 33.6% operating margins, generating $2.62B in TTM free cash flow from a fortress balance sheet with effectively zero debt. While the stock trades ~37% below its 52-week high and below its 200-day moving average, the underlying business fundamentals remain exceptional with expanding margins, robust FCF generation, and aggressive capital returns. The forward P/E of 31.6x with a PEG of 1.76 prices in continued ~20% EPS growth, historically achievable for this quality compounder.
Macro: Hawkish Fed surprise on Sep 16, 2026: FOMC hiked rates (not cut), triggering sharp equity sell-off with Dow down 600 points and S&P 500/Nasdaq falling; 10-year Treasury yield elevated just below 5% with bond yield jitters lingering; Jamie Dimon publicly cast doubt on the inflation fight saying 'it's not clear to me we've slayed inflation'; risk assets broadly de-rated; crypto sold off on hawkish Fed plus failure of CLARITY Act in Senate. Prediction market signals (Polymarket): Fed rate cut by Oct 2026 at 2% (down 1.9pp week-over-week), Fed cut by Dec 2026 at 4% (down 2.1pp wow), Fed cut by April 2027 at 53%, Fed cut by July 2027 at 50%, US recession by end-2026 at 10% (+3pp wow). Markets pricing near-zero chance of Fed relief through year-end—tougher environment for long-duration, high-multiple growth equities like ISRG.